# A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

> **NCT06695897** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 150 (estimated)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06695897
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-05-29
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- Regeneron Pharmaceuticals

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06695897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06695897, "A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT06695897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*